B Lymphocyte News and Research

RSS

Interim data from long-term extension Tecfidera® (dimethyl fumarate) study

Biogen (NASDAQ: BIIB) will, this week, present data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, demonstrating the efficacy and safety of TECFIDERA® (dimethyl fumarate) across a broad range of people with relapsing-remitting multiple sclerosis (RRMS).

7 Oct 2015

Nivolumab, ipilimumab duo effective in poor prognosis advanced melanoma patients

Subgroups of advanced melanoma patients with a poor prognosis derive a progression-free survival benefit from the combination of nivolumab and ipilimumab, according to research presented at the European Cancer Congress in Vienna, Austria.

5 Oct 2015

Study uncovers new mechanisms that regulate immune cells

The proteins CD47 and SIRPα are fundamental to establishing a correct number of immune cells, so-called B lymphocytes. This according to a dissertation by Shrikant Shanital Kolan from Umeå University in Sweden.

22 Sep 2015

Two international business awards won by Aquios CL flow cytometer

Beckman Coulter Life Sciences has gained two prestigious business awards for its clinical flow cytometer, the Aquios CL Flow Cytometer.

From Beckman Coulter Life Sciences - Flow Cytometry 16 Sep 2015

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of an exclusive worldwide license agreement to further develop and commercialize DT2219ARL, a novel therapy for the treatment of various human B cell cancers, leukemias and lymphomas.

8 Sep 2015

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

United Therapeutics Corporation announced today that the European Commission (EC) has granted Marketing Authorisation for Unituxin (dinutuximab) for the treatment of high-risk neuroblastoma in patients aged 12 months to 17 years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (ASCT).

17 Aug 2015

Research: Critical aspects of human genome's regulatory program encoded by genomic sequence elements

Since the classical studies of Jacob and Monod in the early 1960s, it has been evident that genome sequences contain not only blueprints for genes and the proteins that they encode, but also the instructions for a coordinated regulatory program that governs when, where and to what extent these genes and proteins are expressed.

4 Aug 2015

Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

Regeneron Pharmaceuticals, Inc. and Sanofi have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology.

28 Jul 2015

InnaVirVax presents positive results of IVVAC-3S/P1 study at International AIDS Society Conference

InnaVirVax, a biopharmaceutical company specialized in research and development of therapeutic and diagnostic solutions for major infectious and chronic diseases, today announced the overall results of its Phase I/IIa clinical study of its VAC-3S immunotherapy, which is currently in development.

22 Jul 2015

New treatment option available for CLL patients in Manitoba and Saskatchewan

People in Manitoba and Saskatchewan living with Chronic Lymphocytic Leukemia (CLL) will now be able to access a new treatment option through the prescription drug insurance plans in both provinces. Earlier this week, GAZYVA (obinutuzumab) in combination with chlorambucil chemotherapy was added to benefits formularies of the Provincial Oncology Drug Programs at CancerCare Manitoba and the Saskatchewan Cancer Agency.

6 Jul 2015

Damon Runyon creates new award to increase number of physician-scientists

Physician-scientists are crucial to moving scientific discoveries from the lab to patients, but their numbers have been dwindling just when they are needed most, particularly in cancer research, as the number of cancer cases is projected to increase by 45 percent in the next fifteen years and elevate cancer to the leading cause of death in America.

1 Jul 2015

Regulatory T cells critical for the immune system's ability to fight off future pathogen attacks

Just as militaries need to have trained, experienced soldiers ready for future wars, making sure that the immune system has enough battle-ready T cells on hand is important for fast-acting, more effective vaccines, according to Penn State researchers.

17 Jun 2015

Modifying small white blood cells may help treat immune disorders

Modifying the small white blood cells that protect against disease might help treat immune disorders, according to a study published in Cellular and Molecular Gastroenterology and Hepatology, the basic science journal of the American Gastroenterological Association.

16 Jun 2015

Massey researchers aim to develop models that can predict complications from stem cell transplantation

Researchers at VCU Massey Cancer Center's Bone Marrow Transplant Program have recently published findings from a phase 2 clinical trial that demonstrate lymphocyte recovery in related and unrelated stem cell transplant recipients generally falls into three patterns that are significantly associated with survival.

10 Jun 2015

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

AstraZeneca and MedImmune, the company’s global biologics research and development arm, today presented encouraging results from their novel combination-focused immuno-oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015.

2 Jun 2015

MEDI4736 and tremelimumab combination shows acceptable safety, potential efficacy in NSCLC patients

Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.

29 May 2015

FDA clears AQUIOS CL Flow Cytometer for routine immunophenotyping applications in US clinical labs

Beckman Coulter’s new, automated AQUIOS CL Flow Cytometer has received clearance from the U.

From Beckman Coulter Life Sciences - Flow Cytometry 5 May 2015

Pembrolizumab effective, well-tolerated in advanced melanoma patients

Compared with ipilimumab, treatment with pembrolizumab not only significantly improves outcomes, but also results in fewer high-grade adverse events in patients with advanced melanoma, a phase III trial shows.

30 Apr 2015

Cardio3 BioSciences reports absence of short term adverse events in first patient following NKG2D CAR T-cell infusion

Cardio3 BioSciences, soon to be renamed Celyad, a leader in engineered cell-therapy treatments today announced the infusion of the first patient enrolled in the Company’s Phase I clinical trial evaluating the safety and feasibility of its NKG2D CAR T-cell therapy, in cancer patients suffering from acute myeloid leukemia (AML) or multiple myeloma (MM).

22 Apr 2015

New drug combination shows promise in patients with metastatic melanoma

Once again, researchers at Penn's Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, this time by combining the checkpoint inhibitor tremelimumab with an anti-CD40 monoclonal antibody drug.

20 Apr 2015